Literature DB >> 21939916

C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis.

Dan Turner1, David R Mack, Jeffrey Hyams, Neal LeLeiko, Anthony Otley, James Markowitz, Yair Kasirer, Aleixo Muise, Cynthia H Seow, Mark S Silverberg, Wallace Crandall, Anne M Griffiths.   

Abstract

BACKGROUND: There has not been an extensive comparison of CRP and ESR in ulcerative colitis (UC), and thus, we aimed to explore their utility in UC.
METHODS: Four previously enrolled cohorts of 451 children with UC were utilized, all including laboratory, clinical and endoscopic data. A longitudinal analysis was performed on prospectively collected data of 75 children. Disease activity was captured by both global assessment and pediatric UC activity index (PUCAI).
RESULTS: The best thresholds to differentiate quiescent, mild, moderate and severe disease activity, were <23, 23-29, 30-37, >37 mm/h for ESR, and <2.5, 2.5-5, 5.01-9, >9 mg/L for CRP (area under the ROC curves 0.70-0.81). Correlation of endoscopic appearance with CRP and ESR were 0.55 and 0.41, respectively (P<0.001). Both CRP and ESR may be completely normal in 34% and 5-10% of those with mild and moderate-severe disease activity, respectively. Elevated CRP in the presence of normal ESR or vice versa was noted in 32%, 38%, 30% and 17% of those with quiescent, mild, moderate and severe disease activity. Over time, the utility of CRP and ESR in reflecting disease activity remained stable in 70-80% of cases.
CONCLUSION: In ~2/3 of children, both CRP and ESR values reflect disease activity to a similar degree and in the remaining, either CRP or ESR may be sufficient, with slight superiority of CRP. CRP is more closely correlated with endoscopic appearance. When either CRP or ESR performs well for a given patient, this is likely to remain so over time. Therefore, it may not be justified to routinely test both ESR and CRP in monitoring disease activity.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21939916     DOI: 10.1016/j.crohns.2011.05.003

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  11 in total

1.  C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study.

Authors:  Aleksandra Glapa-Nowak; Mariusz Szczepanik; Aleksandra Banaszkiewicz; Jarosław Kwiecień; Anna Szaflarska-Popławska; Urszula Grzybowska-Chlebowczyk; Marcin Osiecki; Jarosław Kierkuś; Marcin Dziekiewicz; Jarosław Walkowiak
Journal:  Med Sci Monit       Date:  2022-09-14

2.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

3.  Inflammatory bowel disease in Turkish children.

Authors:  Murat Cakir; Fatih Unal; Gonul Dinler; Masallah Baran; Hasan Ali Yuksekkaya; Gokhan Tumgor; Erhun Kasirga; Ayhan Gazi Kalayci; Sema Aydogdu
Journal:  World J Pediatr       Date:  2015-10-11       Impact factor: 2.764

4.  First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

Authors:  Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

5.  Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Xue-Liang Jiang; Hua-Hong Wang; Hui-Fei Cui
Journal:  Med Sci Monit       Date:  2015-01-13

6.  Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial.

Authors:  Nikhil Pai; Jelena Popov
Journal:  BMJ Open       Date:  2017-08-21       Impact factor: 2.692

7.  Increased Gene Copy Number of DEFA1A3 Is Associated With the Severity of Ulcerative Colitis.

Authors:  Shuji Kanmura; Yuko Morinaga; Akihito Tanaka; Yuga Komaki; Hiromichi Iwaya; Kotaro Kumagai; Seiichi Mawatari; Fumisato Sasaki; Shiroh Tanoue; Shinichi Hashimoto; Yoichi Sameshima; Yohei Ono; Hidehisa Ohi; Akio Ido
Journal:  Clin Transl Gastroenterol       Date:  2021-04-06       Impact factor: 4.396

8.  Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.

Authors:  David Groeger; Liam O'Mahony; Eileen F Murphy; John F Bourke; Timothy G Dinan; Barry Kiely; Fergus Shanahan; Eamonn M M Quigley
Journal:  Gut Microbes       Date:  2013-06-21

9.  Reducing inappropriate ESR testing with computerized clinical decision support.

Authors:  Stephanie Gottheil; Ekta Khemani; Katherine Copley; Michael Keeney; Jeff Kinney; Ian Chin-Yee; Alan Gob
Journal:  BMJ Qual Improv Rep       Date:  2016-04-04

10.  Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease.

Authors:  Suruchi K Batra; Christopher R Heier; Lina Diaz-Calderon; Christopher B Tully; Alyson A Fiorillo; John van den Anker; Laurie S Conklin
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.